Inactive Instrument

Other languages Kuros Biosciences AG Swiss Exchange

Equities

CH0325814116

Real-time Estimate Cboe Europe Other stock markets 06:04:46 08/07/2024 pm IST			5-day change	1st Jan Change
11.28 ^CHF	+370.00%		+0.42%	+3.91%

24/04	Kuros Biosciences Posts Higher Q1 Product Sales	MT
17/04	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kuros publiziert Daten aus "MagnetOs MAXA Level 1"-Studie in Fachzeitschrift	25/06
Bourse Zurich: retour dans le rouge, Roche plombe l'indice	24/04
Les ventes de Kuros s'envolent	24/04
Kuros mit erneut starkem Umsatz- und Ergebnissprung im ersten Quartal	24/04
Kuros Biosciences Posts Higher Q1 Product Sales	24/04
Kuros Biosciences AG Approves Board of Director and Committee Changes	17/04
Bourse Zurich: le SMI poursuit sa progression, nouveau plus haut de l'année	13/03
Bourse Zurich: les indices passent l'épaule en fin de matinée	13/03
Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up	13/03
Kuros toujours dans le rouge en 2023 malgré des recettes plus que doublées	13/03
Kuros hat nach Umsatzsprung den Verlust verringert	13/03
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Bourse Zurich: dans le rouge avant la Fed, Novartis pèse sur le SMI	31/01
US FDA Approves Kuros Biosciences' Bone Graft Granules for Interbody Use	31/01
Kuros: nouvelles autorisations pour Magnetos aux USA et en Nouvelle-Zélande	31/01
Kuros erhält weitere Zulassung für MagnetOs in den USA und Neuseeland	31/01
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand	31/01
Kuros stellt neue Daten vor und erhält zwei weitere FDA-Zulassungen	04/01
Kuros obtient deux nouvelles autorisations de la FDA et avance sur Magnetos	04/01
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	04/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kuros Biosciences AG Swiss Exchange

Equities

CH0325814116

Other languages

Filters